EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed, Tumor Metabolism Regulated (TMR) CAR-T Product at ASCO GI 2025
Nodose-limiting toxicities, severe adverse events ,or on-target off-tumor toxicities across all dose cohorts Deep and durable response observed in gastroesophageal cancer EXUMA now advancing its clinically de-risked solid tumor & hematologic CARs within vivo GCARTM platform and SCL mRNA technology WEST PALM BEACH, FL – January 23, 2025 /PRNewswire/ –EXUMA Biotech, Corp., a clinical-stage biotechnology […]
EXUMA Biotech Presents Early Clinical and Translational Findings from Solid Tumor Cell Therapy and In Vivo CAR Engineering Research at the AACR Annual Meeting 2023
WEST PALM BEACH, Fla., April 17, 2023 — EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological tumors, presented a poster entitled “In vivo delivery of CD3-directed CD19-CAR lentivectors leads to the generation of CAR T and NK-like (CAR-TaNK) cells capable of complete ablation of B […]
Dr. Sid Kerkar speaks with CGT Live about how EXUMA’s TaNK platforms aim to make CAR therapy safer and faster through novel lentivector engineering
Click here to read the full article
EXUMA Biotech to Present at the 2022 Cancer Immunology and Immunotherapy Conference and to Participate in the 7th Annual CAR-TCR Summit
WEST PALM BEACH, Fla., Sept. 16, 2022 — EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological tumors, announced that pre-clinical data from its solid-tumor subcutaneous CAR therapy program will be presented at the virtual 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology hosted by the Center […]
EXUMA Biotech to Participate in the Upcoming Baird Global Healthcare Investor Conference
WEST PALM BEACH, Fla., Sept. 8, 2022 — EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological tumors, announced today that its Chief Business Officer and Head of Finance, Dr. Gregory Wade, will provide a corporate presentation at 11:25 AM ET on Wednesday, September 14, 2022, as part of […]
EXUMA Biotech Announces Participation in the In Vivo Engineering of Therapeutic Cells Summit
West Palm Beach, Florida- July 6th, 2022- EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors, announced that Dr. Sid Kerkar, the company’s Vice President of Oncology, Research and Development, will participate in the In Vivo Engineering of Therapeutic Cells Summit organized by Hanson Wade […]
Dr. Sid Kerkar talks to OncologyTube about EXUMA’s rPOC SC and in vivo GCAR programs
From OncologyTube: “EXUMA Biotech’s VP of Oncology R&D, Dr. Sid Kerkar, Reveals Preclinical Data From Its Subcutaneous CAR-TaNK And In Vivo CAR Cell And Gene Therapy Programs” EXUMA Biotech’s Subcutaneous CAR-TaNK and In Vivo CAR Cell And Gene Therapy Programs @EXUMABiotech #celltherapy #genetherapy #biotech
Dr. Sid Kerkar talks to VJHemOnc at AACR 2022 about rPOC SC
From VJHemOnc: “Sid P. Kerkar, MD, Exuma Biotech, West Palm Beach, FL, gives an overview of a novel subcutaneous chimeric antigen receptor T-cell (CAR-T) therapy consisting of both T-cell and natural killer (NK) features. Dr Kerkar briefly summarizes the underlying biology of this novel CAR-T treatment, as well as the short manufacturing period required for […]
EXUMA Biotech to Present Preclinical Data from its Subcutaneous CAR-TaNK and In Vivo CAR Cell and Gene Therapy Programs at the American Association for Cancer Research Annual Meeting
West Palm Beach, Florida- March 15, 2022- EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors, announced that preclinical data from its novel, subcutaneous CAR-TaNK therapy for hematological tumors, and in vivo engineered CAR gene therapy program (GCAR), will be presented in two posters at […]
EXUMA Biotech Completes Series B2 to Advance Novel Cell & Gene Therapies
West Palm Beach, Fl., – December 21st, 2021- EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, today announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 […]
